Erdafitinib: adverse event reports filed with FDA

538

reports as suspect product

0% of all reports · about 75 a year

19

reports, 12 months to June 2026

37 in the 12 months before

85.7%

marked serious by the reporter

70.8% across the class

26%

record death among outcomes, as reported

140 reports · not verified by FDA

Reports by month, five years

Reports by the month FDA received them. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

By year received

2026 covers reports received through June 2026 only.

Reactions recorded in the reports

share of Erdafitinib reports recording the termmedian drug in kinase inhibitor

1. Deaththe patient died; cause not stated by this term17.5%94
2. Diarrhoealoose or frequent stools6.9%37
3. Disease progressionthe disease advanced5.4%29
4. Mucosal inflammation5%27
5. Off label useused for a purpose or in a way not on the label4.6%25
6. Onycholysis4.5%24
7. Drug ineffectivethe medicine did not work as expected3.9%21
8. Fatiguetiredness3.5%19
9. Hyperphosphataemia3.3%18
10. Decreased appetitereduced appetite3.2%17
11. Stomatitissore mouth3.2%17
12. Astheniaweakness or lack of energy2.8%15
13. Dry eyedry eye2.8%15
14. Ocular toxicity2.2%12
15. Cataractclouding of the eye lens2%11
16. Palmar-plantar erythrodysaesthesia syndrome2%11
17. Vomitingbeing sick1.9%10
18. Blood phosphorus increased1.7%9
19. Dry mouthdry mouth1.7%9
20. Malignant neoplasm progression1.7%9
21. Nail disorder1.7%9
22. Nauseafeeling sick1.7%9
23. Transitional cell carcinoma1.7%9
24. Adverse drug reactiona harmful or unpleasant reaction reported to a medicine1.5%8
25. Constipationconstipation1.3%7
26. Deep vein thrombosisa blood clot in a deep vein1.3%7
27. Hospitalisationadmission to hospital1.3%7
28. Hypotensionlow blood pressure1.3%7
29. Nail toxicity1.3%7
30. Pulmonary embolisma blood clot in the lung1.3%7

Top 30 of 112 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the median share across the 100 drugs in the kinase inhibitor class; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Outcomes recorded

Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 849,161 reports in the class. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."

Patients and reporters

Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 45.9% of reports give the United States as the country of the event or reporter.

Reason for use recorded

The indication field is filled in by the reporter and is often blank; shares are of all 538 reports.

In context

Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Other drugs in the kinase inhibitor class

Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." A brand and its generic are separate rows because reporters name them separately.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists Erdafitinib as a suspect or interacting product; reports listing it only as a concomitant medication (12) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.